2 terminated. 2 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Terminated 2 |
| Phase 1 | 1 | Terminated 1 |
Follow Relapsed Acute Myeloid Leukemia: new trials by email Literature Review of Relapsed Acute Myeloid Leukemia trials Research Report on Relapsed Acute Myeloid Leukemia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Evaluate Lanraplenib (LANRA) in Combination With Gilteritinib in Participants With FLT3-mutated Relapsed or Refractory Acute Myeloid Leukemia (AML) Lanraplenib, Gilteritinib - Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia | Phase 1 / Phase 2 | Terminated | Kronos Bio | 24 | 2022-08-05 | 2024-08-07 |
| Flotetuzumab for Relapsed Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) Following Allogeneic Hematopoietic Cell Transplantation (Allo-HCT) Flotetuzumab, Donor lymphocyte infusion - Relapsed Acute Myeloid Leukemia | Phase 2 | Terminated | Washington University School of Medicine | 11 | 2021-05-20 | 2024-12-06 |
Hematologic Diseases (2) · Hemic and Lymphatic Diseases (2) · Leukemia (2) · Leukemia, Myeloid (2) · Neoplasms (2) · Neoplasms by Histologic Type (2)
gilteritinib (1)
Kronos Bio (1) · Washington University School of Medicine (1)
United States (2) · Spain (1)
Matthew Christopher, M.D., Ph.D. (1)
P50CA171963 (1)